SI0719859T1 - Anti-alpha V-integrin monoclonal antibody - Google Patents

Anti-alpha V-integrin monoclonal antibody

Info

Publication number
SI0719859T1
SI0719859T1 SI9530683T SI9530683T SI0719859T1 SI 0719859 T1 SI0719859 T1 SI 0719859T1 SI 9530683 T SI9530683 T SI 9530683T SI 9530683 T SI9530683 T SI 9530683T SI 0719859 T1 SI0719859 T1 SI 0719859T1
Authority
SI
Slovenia
Prior art keywords
alpha
monoclonal antibody
integrin monoclonal
integrin
antibody
Prior art date
Application number
SI9530683T
Other languages
English (en)
Slovenian (sl)
Inventor
Francesc Mitjans
Jaume Adan
Jaume Piulats
Simon Goodman
Elisabet Rosell
Diane Hahn
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI0719859(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SI0719859T1 publication Critical patent/SI0719859T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SI9530683T 1994-12-20 1995-12-06 Anti-alpha V-integrin monoclonal antibody SI0719859T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94120165 1994-12-20
EP95119233A EP0719859B1 (en) 1994-12-20 1995-12-06 Anti-alpha V-integrin monoclonal antibody

Publications (1)

Publication Number Publication Date
SI0719859T1 true SI0719859T1 (en) 2003-12-31

Family

ID=8216547

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9530683T SI0719859T1 (en) 1994-12-20 1995-12-06 Anti-alpha V-integrin monoclonal antibody

Country Status (26)

Country Link
US (1) US5985278A (fi)
EP (1) EP0719859B1 (fi)
JP (1) JP3898245B2 (fi)
KR (1) KR100450368B1 (fi)
CN (1) CN1117763C (fi)
AR (1) AR001778A1 (fi)
AT (1) ATE244306T1 (fi)
AU (1) AU710234B2 (fi)
BR (1) BR9505980B1 (fi)
CA (1) CA2165573C (fi)
CO (1) CO4480042A1 (fi)
CZ (1) CZ290477B6 (fi)
DE (1) DE69531187T2 (fi)
DK (1) DK0719859T3 (fi)
ES (1) ES2202336T3 (fi)
FI (1) FI118536B (fi)
HU (1) HU221061B1 (fi)
NO (1) NO321186B1 (fi)
PL (1) PL182961B1 (fi)
PT (1) PT719859E (fi)
RU (1) RU2205223C2 (fi)
SI (1) SI0719859T1 (fi)
SK (1) SK284932B6 (fi)
TR (1) TR199501614A2 (fi)
UA (1) UA40621C2 (fi)
ZA (1) ZA9510806B (fi)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4134497A (en) * 1996-09-03 1998-03-26 Chugai Seiyaku Kabushiki Kaisha Anti-integrin alpha3 antibody complexes
EP0846702B1 (en) * 1996-12-09 2009-03-11 MERCK PATENT GmbH Soluble recombinant alphaV beta3 adhesion receptor
NZ515955A (en) * 1997-08-08 2003-04-29 Univ California Hybridoma producing a monoclonal antibody against beta-6 integrin
PL341569A1 (en) * 1998-01-23 2001-04-23 Merck Patent Gmbh Monoclonal anti-alphav-integrin antibody and application thereof as an inhibitore of alphavbeta6-integrin to fibronectin bond
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
US7064180B2 (en) 2000-07-31 2006-06-20 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7153944B2 (en) * 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7323552B2 (en) * 2000-07-31 2008-01-29 The General Hospital Corporation Variant integrin polypeptides and uses thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
EP1372720A4 (en) * 2001-03-02 2006-07-26 Medimmune Inc PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING ANTAGONISTS OF INTEGRIN ALPHA V BETA 3
PL363311A1 (en) 2001-04-24 2004-11-15 Merck Patent Gmbh Combination therapy using anti-angiogenic agents and tnfalpha
CA2453403C (en) 2001-07-09 2013-10-08 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity
US7829087B2 (en) * 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
CA2478317A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
EP1487492A4 (en) * 2002-03-04 2008-10-01 Medimmune Inc PREVENTION OR TREATMENT OF CANCER USING INTEGRIN ALPHAVBETA3 ANTAGONISTS COMBINED WITH OTHER AGENTS
ME00804B (me) * 2002-03-13 2012-03-20 Biogen Idec Inc Anti-alpha v beta 6 antitela
CN100509851C (zh) * 2002-03-13 2009-07-08 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
US20040048312A1 (en) * 2002-04-12 2004-03-11 Ronghao Li Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
CA2481747A1 (en) * 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
US20040176272A1 (en) * 2003-01-30 2004-09-09 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
EP1613273B1 (en) * 2003-04-11 2012-06-13 MedImmune, LLC Recombinant il-9 antibodies and uses thereof
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
EP1809326A4 (en) 2004-10-27 2009-11-04 Medimmune Inc MODULATION OF ANTIBODY SPECIFICITY BY MEASURING ADAPTATION OF ITS AFFINITY TO AN APPARENT ANTIGEN
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
NZ571068A (en) 2006-03-21 2012-06-29 Genentech Inc An antibody that can bind human alpha5beta1
EP2046374A4 (en) 2006-07-10 2010-05-05 Biogen Idec Inc COMPOSITIONS AND METHODS FOR GROWTH INHIBITION OF SMAD4-DEFICIENT TUMORS
WO2008008373A2 (en) 2006-07-11 2008-01-17 Arubor Corp Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
CA3177366A1 (en) 2006-08-10 2008-02-21 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
WO2008141276A1 (en) * 2007-05-11 2008-11-20 Centocor, Inc. Anti-alpha-v immunoliposome composition, methods and uses
WO2008141274A1 (en) * 2007-05-11 2008-11-20 Centocor, Inc. Anti-alpha v immunoliposome composition, methods and uses
EP2167128B1 (en) 2007-07-17 2012-10-24 Merck Patent GmbH Engineered anti-alpha v- integrin hybrid antibodies
CL2008002856A1 (es) 2007-09-26 2009-01-16 Genentech Inc Anticuerpo novedoso (anticuerpo anti-integrina a5b1; mol}ecula de ácido nucleico que lo codifica; vector y célula huesped; método de producción; composición farmacéutica que lo comprende; su uso para inhibir la angiogénesis y/o permeabilidad vascular y cáncer entre otras patologías; y método de detección de la integrina a5b1).
PL2368118T3 (pl) 2008-12-23 2014-03-31 Merck Patent Gmbh Biomarkery dla inhibitorów z aktywnością antyangiogeniczną
TWI504409B (zh) 2009-03-25 2015-10-21 Genentech Inc 新穎抗－α５β１抗體及其用途
KR20120106952A (ko) 2009-11-13 2012-09-27 메르크 파텐트 게엠베하 화학요법제가 로딩된 나노입자와 연결된 항 인테그린 항체
RU2565539C2 (ru) * 2010-02-18 2015-10-20 Те Риджентс Оф Те Юниверсити Оф Калифорния АНТИТЕЛА, НЕЙТРАЛИЗУЮЩИЕ ИНТЕГРИН ανβ8
WO2012027745A1 (en) * 2010-08-27 2012-03-01 University Of Miami Treatment of renal diseases
PT2672994T (pt) 2011-02-11 2018-10-22 Merck Patent Gmbh Anticorpo anti-integrina alfa-v para o tratamento do cancro da próstata
WO2012143495A2 (de) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
CN103857696B (zh) * 2011-08-17 2017-07-04 加利福尼亚大学董事会 结合整合素αVβ8的抗体
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
EP3086814B1 (de) 2013-12-23 2020-06-24 Bayer Pharma Aktiengesellschaft Binder-konjugate (adcs) mit ksp-inhibitoren
AU2015317411A1 (en) 2014-09-17 2017-04-27 Merck Patent Gmbh A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
JP7372025B2 (ja) 2014-09-17 2023-10-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 固形がんおよび／またはその転移を処置する方法、そのための薬剤、ならびに固形がんおよび／またはその転移処置の臨床転帰を予測する方法
AU2016282723B2 (en) 2015-06-22 2021-09-23 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups
CN107921288A (zh) 2015-06-23 2018-04-17 拜耳医药股份有限公司 Ksp抑制剂的靶向缀合物
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
US20190144547A1 (en) 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
EP3432934B1 (de) 2016-03-24 2022-02-23 Bayer Pharma Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
EP3919518A1 (en) 2016-06-15 2021-12-08 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
JP2019533139A (ja) 2016-09-08 2019-11-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ネフローゼ症候群を診断及び処置するための方法
IL310558A (en) 2016-12-21 2024-03-01 Bayer Pharma AG Drug-antibody conjugates with enzymatically cleavable groups
CN110072556B (zh) 2016-12-21 2023-05-02 拜耳制药股份公司 具有ksp抑制剂的特异性抗体药物缀合物(adc)
CN110312533B (zh) 2016-12-21 2023-11-03 拜耳公司 具有酶促可裂解的基团的细胞毒性活性剂的前药
KR101961715B1 (ko) 2018-07-18 2019-03-25 (주) 삼진정밀 고효율 수처리장치
AU2019362602A1 (en) 2018-10-19 2021-06-03 Merck Patent Gmbh Abituzumab for the treatment of colorectal cancer
KR101999620B1 (ko) 2019-03-26 2019-07-12 조용진 부상슬러지 및 침전슬러지의 동시처리장치
EP3953389A1 (en) * 2019-04-08 2022-02-16 Biogen MA Inc. Anti-integrin antibodies and uses thereof
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE175241T1 (de) * 1992-04-03 1999-01-15 Genentech Inc Antikörper gegen alpha v beta 3 integrin
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis

Also Published As

Publication number Publication date
AU710234B2 (en) 1999-09-16
EP0719859B1 (en) 2003-07-02
HU221061B1 (hu) 2002-07-29
FI118536B (fi) 2007-12-14
DE69531187D1 (de) 2003-08-07
BR9505980A (pt) 1997-12-23
EP0719859A1 (en) 1996-07-03
PL311926A1 (en) 1996-06-24
NO321186B1 (no) 2006-04-03
DK0719859T3 (da) 2003-10-20
SK159295A3 (en) 1996-07-03
NO955167D0 (no) 1995-12-19
ES2202336T3 (es) 2004-04-01
FI956112A0 (fi) 1995-12-19
UA40621C2 (uk) 2001-08-15
AR001778A1 (es) 1997-12-10
CA2165573A1 (en) 1996-06-21
JPH08231597A (ja) 1996-09-10
FI956112A (fi) 1996-06-21
HUT74828A (en) 1997-02-28
HU9503638D0 (en) 1996-02-28
ZA9510806B (en) 1996-05-30
CZ290477B6 (cs) 2002-07-17
KR100450368B1 (ko) 2005-01-31
RU2205223C2 (ru) 2003-05-27
DE69531187T2 (de) 2004-04-22
JP3898245B2 (ja) 2007-03-28
BR9505980B1 (pt) 2010-02-23
CN1117763C (zh) 2003-08-13
NO955167L (no) 1996-06-21
CN1139115A (zh) 1997-01-01
KR960022562A (ko) 1996-07-18
CO4480042A1 (es) 1997-07-09
ATE244306T1 (de) 2003-07-15
PL182961B1 (pl) 2002-05-31
CZ328895A3 (en) 1996-09-11
TR199501614A2 (tr) 1996-07-21
PT719859E (pt) 2003-11-28
SK284932B6 (sk) 2006-02-02
CA2165573C (en) 2011-03-29
US5985278A (en) 1999-11-16
AU4042195A (en) 1996-06-27

Similar Documents

Publication Publication Date Title
SI0719859T1 (en) Anti-alpha V-integrin monoclonal antibody
IL128406A0 (en) Monoclonal antibodies
GB9422383D0 (en) Antibodies
AU6702998A (en) Anti-alphabeta3 humanized monoclonal antibodies
EP0578515A3 (en) Humanized monoclonal antibodies.
EP0580859A4 (en) Anti-eda monoclonal antibody
GB9608626D0 (en) Hepatitis b monoclonal antibodies
EP0909278A4 (en) IMMUNOGLOBULIN G LINKED TO NEPHROPATHY AND ANTIBODIES AGAINST IT
EP0506523A3 (en) Monoclonal antibodies
EP0977590A4 (en) HUMAN MONOCLONAL ANTIBODIES
GB9718911D0 (en) Monoclonal antibodies
ZA951113B (en) Tumor assosiated monoclonal antibody 123av16
EP0654532A4 (en) ANTIMUCOGLYCOPROTEIN MONOCLONAL ANTIBODIES.
AP9801381A0 (en) Anti-human mp52 monoclonal antibody
GB9615027D0 (en) Monoclonal antibodies
SG64332A1 (en) Monoclonal antibody
GB9212074D0 (en) Monoclonal antibody
ZA954678B (en) Monoclonal antibody against cd44v6
GB9406243D0 (en) Antibodies
GB9406222D0 (en) Huminised antibodies
IL134049A0 (en) Anti-cryptdin antibodies
GB9415331D0 (en) Antibodies
GB9401597D0 (en) Altered antibodies
GB9406244D0 (en) Altered antibodies
GB9320508D0 (en) Antibodies